Aerie Pharmaceuticals announced the appointment of Julia Williams as Director of Medical Affairs, reporting to John Maltman, Ph.D., Aerie’s Vice President of Medical Affairs. Williams will participate in directing the strategic and operational activities of the Company’s Medical Affairs organization, initially focused on the launch of Rhopressa (netarsudil ophthalmic solution) 0.02%. She previously held related positions at Ora and Allergan.
In connection with her acceptance of the position as Director of Medical Affairs, Williams will receive awards totaling 14,400 stock options. The stock options will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date. This award was made outside of Aerie’s stockholder-approved equity incentive plan and was approved by the company’s independent directors as an inducement material to Williams entering into employment with the company in reliance on NASDAQ Listing Rule 5635(c)(4).